Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602

Eur J Clin Pharmacol. 1977 Apr 20;11(4):255-61. doi: 10.1007/BF00607673.
No abstract available

MeSH terms

  • Benserazide / administration & dosage
  • Benserazide / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Homovanillic Acid / cerebrospinal fluid*
  • Humans
  • Hydrazines / therapeutic use*
  • Hydroxyindoleacetic Acid / cerebrospinal fluid*
  • Levodopa / administration & dosage
  • Levodopa / blood
  • Levodopa / therapeutic use*
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / metabolism
  • Parkinson Disease / physiopathology
  • Phenylacetates / cerebrospinal fluid*
  • Time Factors

Substances

  • Hydrazines
  • Phenylacetates
  • Levodopa
  • Hydroxyindoleacetic Acid
  • Benserazide
  • Homovanillic Acid